AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
primidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2267 | 125-33-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.25 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.60 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 35 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 98.18 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 92 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.807 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.133 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 10.495 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.550 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 63.530 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 60.600 | % | High | 1 |
| herg | hERG pIC50 | 3.998 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.968 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.170 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 60.490 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PRKDC | 16 | |||
| kinase-selectivity-class | AXL,GRK2,PDK4 | 3 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 1.236 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.330 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 10.914 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 53.680 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 5.875 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 69.270 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.206 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.945 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 92.270 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 50.060 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 926.830 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 8, 1954 | FDA | VALEANT |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 170.13 | 14.06 | 136 | 9498 | 152493 | 90466320 |
| Tremor | 109.28 | 14.06 | 106 | 9528 | 153067 | 90465746 |
| Completed suicide | 108.42 | 14.06 | 103 | 9531 | 144955 | 90473858 |
| Fall | 89.57 | 14.06 | 173 | 9461 | 481637 | 90137176 |
| Petit mal epilepsy | 68.20 | 14.06 | 24 | 9610 | 4934 | 90613879 |
| Ataxia | 57.23 | 14.06 | 31 | 9603 | 18011 | 90600802 |
| Drug interaction | 53.35 | 14.06 | 101 | 9533 | 276352 | 90342461 |
| Drug withdrawal convulsions | 40.02 | 14.06 | 12 | 9622 | 1488 | 90617325 |
| Myoclonic epilepsy | 39.06 | 14.06 | 12 | 9622 | 1615 | 90617198 |
| Anticonvulsant drug level increased | 38.29 | 14.06 | 12 | 9622 | 1724 | 90617089 |
| Somnolence | 37.37 | 14.06 | 74 | 9560 | 209010 | 90409803 |
| Product complaint | 36.80 | 14.06 | 21 | 9613 | 13479 | 90605334 |
| Essential tremor | 36.39 | 14.06 | 11 | 9623 | 1401 | 90617412 |
| Lennox-Gastaut syndrome | 36.10 | 14.06 | 8 | 9626 | 297 | 90618516 |
| Generalised tonic-clonic seizure | 30.33 | 14.06 | 27 | 9607 | 34876 | 90583937 |
| Cerebellar atrophy | 28.37 | 14.06 | 8 | 9626 | 799 | 90618014 |
| Balance disorder | 27.32 | 14.06 | 42 | 9592 | 97038 | 90521775 |
| Diplopia | 26.52 | 14.06 | 23 | 9611 | 28691 | 90590122 |
| Infusion related reaction | 24.46 | 14.06 | 7 | 9627 | 416773 | 90202040 |
| Contraindicated product administered | 23.80 | 14.06 | 3 | 9631 | 320136 | 90298677 |
| Hallucination | 23.63 | 14.06 | 32 | 9602 | 65927 | 90552886 |
| Systemic lupus erythematosus | 23.33 | 14.06 | 5 | 9629 | 361891 | 90256922 |
| Urinary tract infection | 22.91 | 14.06 | 78 | 9556 | 305554 | 90313259 |
| Anticonvulsant drug level above therapeutic | 21.65 | 14.06 | 6 | 9628 | 563 | 90618250 |
| Multiple sclerosis | 21.19 | 14.06 | 20 | 9614 | 27820 | 90590993 |
| Toxicity to various agents | 21.17 | 14.06 | 73 | 9561 | 287773 | 90331040 |
| Hemianopia | 20.93 | 14.06 | 8 | 9626 | 2074 | 90616739 |
| Joint swelling | 20.81 | 14.06 | 14 | 9620 | 503286 | 90115527 |
| Product substitution issue | 19.90 | 14.06 | 16 | 9618 | 17992 | 90600821 |
| Nystagmus | 19.05 | 14.06 | 11 | 9623 | 7216 | 90611597 |
| Loss of consciousness | 18.57 | 14.06 | 44 | 9590 | 140194 | 90478619 |
| Multiple-drug resistance | 18.30 | 14.06 | 11 | 9623 | 7765 | 90611048 |
| Glossodynia | 17.80 | 14.06 | 6 | 9628 | 321773 | 90297040 |
| Drug ineffective for unapproved indication | 17.59 | 14.06 | 28 | 9606 | 66616 | 90552197 |
| Dysarthria | 17.37 | 14.06 | 25 | 9609 | 54457 | 90564356 |
| Status epilepticus | 17.19 | 14.06 | 15 | 9619 | 18859 | 90599954 |
| Multiple sclerosis relapse | 16.68 | 14.06 | 24 | 9610 | 52281 | 90566532 |
| Rheumatoid arthritis | 16.50 | 14.06 | 9 | 9625 | 362605 | 90256208 |
| Abdominal discomfort | 16.34 | 14.06 | 16 | 9618 | 477312 | 90141501 |
| Product dose omission issue | 15.70 | 14.06 | 67 | 9567 | 291620 | 90327193 |
| Hyperacusis | 15.38 | 14.06 | 7 | 9627 | 2804 | 90616009 |
| Drug intolerance | 15.32 | 14.06 | 15 | 9619 | 447576 | 90171237 |
| Hypokalaemia | 15.10 | 14.06 | 39 | 9595 | 131077 | 90487736 |
| Dyskinesia | 15.06 | 14.06 | 19 | 9615 | 36515 | 90582298 |
| Psoriatic arthropathy | 15.02 | 14.06 | 3 | 9631 | 228332 | 90390481 |
| Gait disturbance | 14.92 | 14.06 | 61 | 9573 | 260435 | 90358378 |
| Deafness transitory | 14.13 | 14.06 | 6 | 9628 | 2037 | 90616776 |
| Dizziness | 14.13 | 14.06 | 109 | 9525 | 589175 | 90029638 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ataxia | 88.07 | 17.33 | 46 | 6959 | 16079 | 42598251 |
| Developmental delay | 76.13 | 17.33 | 26 | 6979 | 3156 | 42611174 |
| Somnolence | 74.22 | 17.33 | 103 | 6902 | 141002 | 42473328 |
| Serotonin syndrome | 70.36 | 17.33 | 47 | 6958 | 25798 | 42588532 |
| Drug interaction | 64.63 | 17.33 | 138 | 6867 | 266861 | 42347469 |
| Growth hormone-producing pituitary tumour | 56.22 | 17.33 | 11 | 6994 | 138 | 42614192 |
| Seizure | 54.56 | 17.33 | 82 | 6923 | 120479 | 42493851 |
| Gastric hypomotility | 52.14 | 17.33 | 11 | 6994 | 205 | 42614125 |
| Shunt malfunction | 49.26 | 17.33 | 11 | 6994 | 270 | 42614060 |
| Viral diarrhoea | 47.63 | 17.33 | 11 | 6994 | 315 | 42614015 |
| Tremor | 46.81 | 17.33 | 68 | 6937 | 96861 | 42517469 |
| Status epilepticus | 46.45 | 17.33 | 30 | 6975 | 15548 | 42598782 |
| Hallucination | 46.25 | 17.33 | 52 | 6953 | 57455 | 42556875 |
| Blood growth hormone increased | 40.20 | 17.33 | 11 | 6994 | 633 | 42613697 |
| Gingival atrophy | 39.97 | 17.33 | 7 | 6998 | 45 | 42614285 |
| Multiple-drug resistance | 37.44 | 17.33 | 20 | 6985 | 7302 | 42607028 |
| Breath odour | 35.38 | 17.33 | 11 | 6994 | 992 | 42613338 |
| Shunt occlusion | 35.12 | 17.33 | 11 | 6994 | 1016 | 42613314 |
| Generalised tonic-clonic seizure | 34.37 | 17.33 | 31 | 6974 | 26348 | 42587982 |
| Infrequent bowel movements | 33.79 | 17.33 | 11 | 6994 | 1151 | 42613179 |
| Fall | 33.20 | 17.33 | 99 | 6906 | 234421 | 42379909 |
| Drug ineffective | 30.65 | 17.33 | 192 | 6813 | 630005 | 41984325 |
| Insulin-like growth factor increased | 30.14 | 17.33 | 11 | 6994 | 1620 | 42612710 |
| Strabismus | 29.64 | 17.33 | 12 | 6993 | 2336 | 42611994 |
| Plantar fascial fibromatosis | 28.62 | 17.33 | 4 | 7001 | 3 | 42614327 |
| Bone metabolism disorder | 28.42 | 17.33 | 7 | 6998 | 265 | 42614065 |
| Open angle glaucoma | 28.37 | 17.33 | 7 | 6998 | 267 | 42614063 |
| Cervicobrachial syndrome | 27.10 | 17.33 | 7 | 6998 | 322 | 42614008 |
| Parkinsonian rest tremor | 27.06 | 17.33 | 7 | 6998 | 324 | 42614006 |
| Pleocytosis | 26.46 | 17.33 | 8 | 6997 | 657 | 42613673 |
| Foot deformity | 26.35 | 17.33 | 14 | 6991 | 5054 | 42609276 |
| Acute kidney injury | 26.07 | 17.33 | 14 | 6991 | 367323 | 42247007 |
| Completed suicide | 25.71 | 17.33 | 52 | 6953 | 96413 | 42517917 |
| Cerebellar atrophy | 25.43 | 17.33 | 8 | 6997 | 750 | 42613580 |
| Helicobacter infection | 25.04 | 17.33 | 11 | 6994 | 2621 | 42611709 |
| Product use issue | 24.92 | 17.33 | 45 | 6960 | 76706 | 42537624 |
| Encephalopathy | 24.43 | 17.33 | 32 | 6973 | 41301 | 42573029 |
| Focal dyscognitive seizures | 23.82 | 17.33 | 9 | 6996 | 1458 | 42612872 |
| Gingival disorder | 23.21 | 17.33 | 9 | 6996 | 1565 | 42612765 |
| Lens dislocation | 21.93 | 17.33 | 5 | 7000 | 135 | 42614195 |
| Eye movement disorder | 21.13 | 17.33 | 12 | 6993 | 4933 | 42609397 |
| Brain injury | 21.00 | 17.33 | 14 | 6991 | 7641 | 42606689 |
| Nosocomial infection | 20.43 | 17.33 | 8 | 6997 | 1428 | 42612902 |
| Nystagmus | 20.16 | 17.33 | 12 | 6993 | 5384 | 42608946 |
| Obsessive-compulsive disorder | 20.13 | 17.33 | 13 | 6992 | 6730 | 42607600 |
| Eructation | 19.97 | 17.33 | 12 | 6993 | 5474 | 42608856 |
| Balance disorder | 19.52 | 17.33 | 31 | 6974 | 47614 | 42566716 |
| Anticonvulsant drug level above therapeutic | 17.73 | 17.33 | 6 | 6999 | 707 | 42613623 |
| Jaw disorder | 17.38 | 17.33 | 8 | 6997 | 2125 | 42612205 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Completed suicide | 139.19 | 14.20 | 157 | 12932 | 242224 | 110333986 |
| Ataxia | 133.29 | 14.20 | 67 | 13022 | 30041 | 110546169 |
| Seizure | 123.10 | 14.20 | 141 | 12948 | 221044 | 110355166 |
| Drug interaction | 118.54 | 14.20 | 212 | 12877 | 499971 | 110076239 |
| Tremor | 112.65 | 14.20 | 129 | 12960 | 202103 | 110374107 |
| Fall | 93.03 | 14.20 | 214 | 12875 | 603268 | 109972942 |
| Somnolence | 75.38 | 14.20 | 130 | 12959 | 297319 | 110278891 |
| Developmental delay | 75.15 | 14.20 | 20 | 13069 | 1445 | 110574765 |
| Growth hormone-producing pituitary tumour | 59.38 | 14.20 | 11 | 13078 | 144 | 110576066 |
| Hallucination | 53.55 | 14.20 | 63 | 13026 | 101369 | 110474841 |
| Gastric hypomotility | 51.95 | 14.20 | 11 | 13078 | 294 | 110575916 |
| Shunt malfunction | 49.84 | 14.20 | 11 | 13078 | 359 | 110575851 |
| Serotonin syndrome | 49.55 | 14.20 | 47 | 13042 | 59106 | 110517104 |
| Petit mal epilepsy | 49.40 | 14.20 | 22 | 13067 | 7525 | 110568685 |
| Status epilepticus | 47.08 | 14.20 | 35 | 13054 | 31536 | 110544674 |
| Viral diarrhoea | 44.66 | 14.20 | 11 | 13078 | 583 | 110575627 |
| Cerebellar atrophy | 43.41 | 14.20 | 13 | 13076 | 1440 | 110574770 |
| Multiple-drug resistance | 43.09 | 14.20 | 24 | 13065 | 13211 | 110562999 |
| Generalised tonic-clonic seizure | 41.21 | 14.20 | 41 | 13048 | 54639 | 110521571 |
| Lennox-Gastaut syndrome | 40.53 | 14.20 | 9 | 13080 | 302 | 110575908 |
| Gingival atrophy | 38.75 | 14.20 | 7 | 13082 | 79 | 110576131 |
| Blood growth hormone increased | 38.26 | 14.20 | 11 | 13078 | 1057 | 110575153 |
| Nystagmus | 37.71 | 14.20 | 21 | 13068 | 11556 | 110564654 |
| Toxicity to various agents | 35.38 | 14.20 | 131 | 12958 | 480424 | 110095786 |
| Parkinsonian rest tremor | 33.09 | 14.20 | 8 | 13081 | 392 | 110575818 |
| Shunt occlusion | 32.99 | 14.20 | 11 | 13078 | 1726 | 110574484 |
| Anticonvulsant drug level above therapeutic | 32.19 | 14.20 | 10 | 13079 | 1252 | 110574958 |
| Breath odour | 31.51 | 14.20 | 11 | 13078 | 1981 | 110574229 |
| Drug ineffective for unapproved indication | 31.47 | 14.20 | 49 | 13040 | 102789 | 110473421 |
| Infrequent bowel movements | 30.57 | 14.20 | 11 | 13078 | 2164 | 110574046 |
| Insulin-like growth factor increased | 29.99 | 14.20 | 11 | 13078 | 2285 | 110573925 |
| Strabismus | 28.82 | 14.20 | 12 | 13077 | 3487 | 110572723 |
| Essential tremor | 28.40 | 14.20 | 10 | 13079 | 1848 | 110574362 |
| Myoclonic epilepsy | 28.29 | 14.20 | 11 | 13078 | 2680 | 110573530 |
| Anticonvulsant drug level increased | 27.64 | 14.20 | 11 | 13078 | 2847 | 110573363 |
| Balance disorder | 25.69 | 14.20 | 48 | 13041 | 116512 | 110459698 |
| Open angle glaucoma | 25.52 | 14.20 | 7 | 13082 | 567 | 110575643 |
| Bone metabolism disorder | 25.33 | 14.20 | 7 | 13082 | 583 | 110575627 |
| Focal dyscognitive seizures | 24.49 | 14.20 | 11 | 13078 | 3838 | 110572372 |
| Mental status changes | 24.31 | 14.20 | 37 | 13052 | 76085 | 110500125 |
| Gingival disorder | 23.69 | 14.20 | 11 | 13078 | 4142 | 110572068 |
| Anticonvulsant drug level decreased | 23.41 | 14.20 | 9 | 13080 | 2127 | 110574083 |
| Obsessive-compulsive disorder | 23.21 | 14.20 | 13 | 13076 | 7228 | 110568982 |
| Plantar fascial fibromatosis | 22.67 | 14.20 | 4 | 13085 | 39 | 110576171 |
| Choreoathetosis | 21.68 | 14.20 | 8 | 13081 | 1690 | 110574520 |
| Pleocytosis | 21.56 | 14.20 | 8 | 13081 | 1716 | 110574494 |
| Anticoagulation drug level below therapeutic | 21.51 | 14.20 | 8 | 13081 | 1726 | 110574484 |
| Encephalopathy | 21.23 | 14.20 | 36 | 13053 | 81019 | 110495191 |
| Needle issue | 20.58 | 14.20 | 17 | 13072 | 17823 | 110558387 |
| Cervicobrachial syndrome | 20.47 | 14.20 | 7 | 13082 | 1185 | 110575025 |
| Dizziness | 20.47 | 14.20 | 147 | 12942 | 698046 | 109878164 |
| Dysarthria | 20.25 | 14.20 | 36 | 13053 | 84085 | 110492125 |
| Infusion related reaction | 20.09 | 14.20 | 10 | 13079 | 381152 | 110195058 |
| Drug ineffective | 19.81 | 14.20 | 270 | 12819 | 1520270 | 109055940 |
| Inhibitory drug interaction | 18.97 | 14.20 | 10 | 13079 | 4937 | 110571273 |
| Dementia | 18.95 | 14.20 | 21 | 13068 | 31652 | 110544558 |
| Jaw disorder | 18.48 | 14.20 | 10 | 13079 | 5202 | 110571008 |
| Urinary tract infection | 18.44 | 14.20 | 82 | 13007 | 326200 | 110250010 |
| Brain injury | 18.01 | 14.20 | 14 | 13075 | 13462 | 110562748 |
| Hemianopia | 17.62 | 14.20 | 8 | 13081 | 2860 | 110573350 |
| Joint swelling | 17.48 | 14.20 | 16 | 13073 | 442829 | 110133381 |
| Contraindicated product administered | 17.43 | 14.20 | 4 | 13085 | 248263 | 110327947 |
| Eye movement disorder | 17.28 | 14.20 | 12 | 13077 | 9716 | 110566494 |
| Psychomotor retardation | 17.19 | 14.20 | 11 | 13078 | 7781 | 110568429 |
| Oesophageal ulcer | 16.97 | 14.20 | 11 | 13078 | 7953 | 110568257 |
| Lower respiratory tract infection | 16.90 | 14.20 | 4 | 13085 | 243102 | 110333108 |
| Acute kidney injury | 16.81 | 14.20 | 31 | 13058 | 635399 | 109940811 |
| Nosocomial infection | 16.79 | 14.20 | 8 | 13081 | 3191 | 110573019 |
| Lens dislocation | 16.73 | 14.20 | 4 | 13085 | 187 | 110576023 |
| Injection site haemorrhage | 16.57 | 14.20 | 20 | 13069 | 33008 | 110543202 |
| Loss of consciousness | 16.54 | 14.20 | 56 | 13033 | 196250 | 110379960 |
| Maternal exposure during pregnancy | 16.21 | 14.20 | 5 | 13084 | 254878 | 110321332 |
| Overdose | 15.73 | 14.20 | 62 | 13027 | 233732 | 110342478 |
| Febrile neutropenia | 15.68 | 14.20 | 9 | 13080 | 316758 | 110259452 |
| Altered state of consciousness | 15.63 | 14.20 | 26 | 13063 | 57600 | 110518610 |
| Death | 15.47 | 14.20 | 138 | 12951 | 698731 | 109877479 |
| Psychotic symptom | 15.35 | 14.20 | 8 | 13081 | 3859 | 110572351 |
| Multiple sclerosis | 15.30 | 14.20 | 17 | 13072 | 25681 | 110550529 |
| Gait disturbance | 15.02 | 14.20 | 69 | 13020 | 278139 | 110298071 |
| Anticoagulation drug level decreased | 15.01 | 14.20 | 4 | 13085 | 290 | 110575920 |
| Glossodynia | 14.77 | 14.20 | 4 | 13085 | 222000 | 110354210 |
| Upper limb fracture | 14.52 | 14.20 | 15 | 13074 | 20873 | 110555337 |
| Systemic lupus erythematosus | 14.45 | 14.20 | 6 | 13083 | 254332 | 110321878 |
| Stomatitis | 14.37 | 14.20 | 7 | 13082 | 270235 | 110305975 |
| Electroencephalogram abnormal | 14.33 | 14.20 | 9 | 13080 | 6164 | 110570046 |
| International normalised ratio decreased | 14.26 | 14.20 | 10 | 13079 | 8226 | 110567984 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N03AA03 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Barbiturates and derivatives |
| FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018682 | GABA Agents |
| MeSH PA | D018757 | GABA Modulators |
| FDA EPC | N0000175753 | Anti-epileptic Agent |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
Related Drugs by ATC class:
N03AA Barbiturates and derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tonic-clonic seizure | indication | 54200006 | |
| Epilepsy | indication | 84757009 | DOID:1826 |
| Bipolar disorder in remission | indication | 85248005 | |
| Localization-related epilepsy | indication | 230381009 | DOID:2234 |
| Lennox-Gastaut syndrome | indication | 230418006 | |
| Tonic-clonic epilepsy | indication | 352818000 | DOID:7725 |
| Epilepsy characterized by intractable complex partial seizures | indication | 442481002 | |
| Simple partial seizure | indication | 117891000119100 | |
| Bipolar affective disorder, current episode depression | off-label use | 191627008 | DOID:3312 |
| Neuropathic pain | off-label use | 247398009 | |
| Essential tremor | off-label use | 609558009 | DOID:4990 |
| Rapid Cycling Bipolar Affective Disorder | off-label use | ||
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Constitutional aplastic anemia | contraindication | 28975000 | DOID:1342 |
| Depressive disorder | contraindication | 35489007 | |
| Megaloblastic anemia | contraindication | 53165003 | DOID:13382 |
| Acute nephropathy | contraindication | 58574008 | |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Pancytopenia | contraindication | 127034005 | DOID:12450 |
| Non-infective meningitis | contraindication | 230155003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Aplastic anemia | contraindication | 306058006 | DOID:12449 |
| Granulocytopenic disorder | contraindication | 417672002 | |
| Porphyria | contraindication | 418470004 | |
| Primidone Toxicity | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Convulsions associated with idiopathic epilepsy | Indication |
| Dogs | Epileptiform convulsions | Indication |
| Dogs | Viral encephalitis | Indication |
| Dogs | Distemper | Indication |
| Dogs | Hardpad disease | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Primidone | Zoetis Inc. | 1 |
| Mylepsin Tablets | Zoetis Inc. | 1 |
| Mylepsin, Primidone Medi-Pets | Zoetis Inc. | 1 |
| Neurosyn Tablets | Cronus Pharma Specialities India Private Limited | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.99 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | WOMBAT-PK | CHEMBL | |||||
| Transient receptor potential cation channel subfamily M member 3 | Ion channel | BLOCKER | IC50 | 6.20 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018485 | VUID |
| N0000146807 | NUI |
| D00474 | KEGG_DRUG |
| 4018485 | VANDF |
| C0033148 | UMLSCUI |
| CHEBI:8412 | CHEBI |
| A1AIA | PDB_CHEM_ID |
| CHEMBL856 | ChEMBL_ID |
| DB00794 | DRUGBANK_ID |
| D011324 | MESH_DESCRIPTOR_UI |
| 4909 | PUBCHEM_CID |
| 5338 | IUPHAR_LIGAND_ID |
| 248 | INN_ID |
| 13AFD7670Q | UNII |
| 8691 | RXNORM |
| 390 | MMSL |
| 5355 | MMSL |
| d00352 | MMSL |
| 001626 | NDDF |
| 387256009 | SNOMEDCT_US |
| 47120002 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1231 | TABLET | 250 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1301 | TABLET | 50 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5321 | TABLET | 250 mg | ORAL | ANDA | 13 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8206 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-522 | TABLET | 250 mg | ORAL | ANDA | 15 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-540 | TABLET | 50 mg | ORAL | ANDA | 15 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-509 | TABLET | 50 mg | ORAL | ANDA | 16 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-511 | TABLET | 250 mg | ORAL | ANDA | 16 sections |
| PRIMIDONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-680 | TABLET | 50 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-1622 | TABLET | 250 mg | ORAL | ANDA | 13 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-686 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-686 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-687 | TABLET | 250 mg | ORAL | ANDA | 11 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-687 | TABLET | 250 mg | ORAL | ANDA | 11 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-637 | TABLET | 50 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-638 | TABLET | 250 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52817-117 | TABLET | 125 mg | ORAL | ANDA | 15 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-544 | TABLET | 50 mg | ORAL | ANDA | 12 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-545 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-1691 | TABLET | 250 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5067 | TABLET | 50 mg | ORAL | ANDA | 14 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55111-476 | TABLET | 250 mg | ORAL | ANDA | 13 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55111-477 | TABLET | 50 mg | ORAL | ANDA | 13 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-468 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-7811 | TABLET | 50 mg | ORAL | ANDA | 12 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-544 | TABLET | 50 mg | ORAL | ANDA | 12 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-545 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
| Mysoline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66490-690 | TABLET | 50 mg | ORAL | NDA | 15 sections |
| Mysoline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66490-691 | TABLET | 250 mg | ORAL | NDA | 15 sections |
| Primidone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68084-202 | TABLET | 50 mg | ORAL | ANDA | 15 sections |